Impact of Glycoprotein IIb/IIIa Inhibition in Contemporary Percutaneous Coronary Intervention for Acute Coronary Syndromes: Insights From the National Cardiovascular Data Registry.
暂无分享,去创建一个
David J Cohen | D. Cohen | K. Kennedy | D. Safley | Lakshmi Venkitachalam | Kevin F Kennedy | Lakshmi Venkitachalam | David M Safley | D. Cohen | D. Cohen
[1] R. Kronmal,et al. Assessing the sensitivity of regression results to unmeasured confounders in observational studies. , 1998, Biometrics.
[2] Jeffrey L. Anderson,et al. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2008, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[3] J. Ornato,et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). , 2006, Circulation.
[4] Paul R. Rosenbaum,et al. Matched Sampling for Causal Effects: Constructing a Control Group Using Multivariate Matched Sampling Methods That Incorporate the Propensity Score , 2006 .
[5] Christopher E. Buller,et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2008, Circulation.
[6] B. Gersh,et al. Bivalirudin during primary PCI in acute myocardial infarction. , 2008, The New England journal of medicine.
[7] S. Morgan,et al. Matching Estimators of Causal Effects , 2006 .
[8] M. Pencina,et al. Prognostic Implications of Creatine Kinase-MB Elevation After Percutaneous Coronary Intervention: Results From the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) Registry , 2011, Circulation. Cardiovascular interventions.
[9] J. Newhouse,et al. Econometrics in outcomes research: the use of instrumental variables. , 1998, Annual review of public health.
[10] Sebastian Schneeweiss,et al. The International Journal of Biostatistics Preference-Based Instrumental Variable Methods for the Estimation of Treatment Effects : Assessing Validity and Interpreting Results , 2011 .
[11] W. Gibler,et al. Influence of clinical trial enrollment on the quality of care and outcomes for patients with non-ST-segment elevation acute coronary syndromes. , 2005, American heart journal.
[12] A. Detsky,et al. Composite end points in randomized trials: there is no free lunch. , 2010, JAMA.
[13] Carl J Pepine,et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients , 2002, Journal of the American College of Cardiology.
[14] K. Alexander,et al. Changes in glycoprotein IIb/IIIa inhibitor excess dosing with site-specific safety feedback in the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines (CRUSADE) initiative. , 2010, American heart journal.
[15] Epic Investigators,et al. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. , 1994, The New England journal of medicine.
[16] Jörg Hausleiter,et al. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. , 2011, The New England journal of medicine.
[17] R. Califf,et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. , 2009, The New England journal of medicine.
[18] K. Alexander,et al. Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION Registry--GWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry--Get With the Guidelines). , 2010, JACC. Cardiovascular interventions.
[19] M. Mack,et al. Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI). , 2013, Journal of the American College of Cardiology.
[20] D. Rubin,et al. Constructing a Control Group Using Multivariate Matched Sampling Methods That Incorporate the Propensity Score , 1985 .
[21] J. Tu,et al. Ecological Studies and Cardiovascular Outcomes Research , 2008, Circulation.
[22] V. Hasselblad,et al. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. , 2001 .
[23] E. DeLong,et al. Optimal Timing of Intervention in Non–ST-Segment Elevation Acute Coronary Syndromes: Insights From the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Registry , 2005, Circulation.
[24] J. Rassen,et al. Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention. , 2010, European heart journal.
[25] Jane A. Linderbaum,et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.
[26] G. Lamas,et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.
[27] V. Prasad,et al. Prespecified falsification end points: can they validate true observational associations? , 2013, JAMA.
[28] H. White,et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes , 2002, The Lancet.
[29] Aziz Ahmed,et al. Glycoprotein IIb/IIIa inhibitors with or without thienopyridine pretreatment improve outcomes after primary percutaneous coronary intervention in high‐risk patients with ST elevation myocardial infarction—a meta‐regression of randomized controlled trials , 2013, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[30] M. Pencina,et al. Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients: results from the EVENT (evaluation of drug-eluting stents and ischemic events) registry. , 2009, JACC. Cardiovascular interventions.
[31] Adelaide,et al. Bivalirudin for patients with acute coronary syndromes. , 2006, The New England journal of medicine.
[32] Epilog Investigators,et al. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. , 1997, The New England journal of medicine.
[33] E. Topol. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade , 1998, The Lancet.
[34] Hani Jneid,et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Forc , 2012, Journal of the American College of Cardiology.
[35] B J McNeil,et al. Does more intensive treatment of acute myocardial infarction in the elderly reduce mortality? Analysis using instrumental variables. , 1994, JAMA.
[36] P. Chan,et al. Survival Benefit With Drug-Eluting Stents in Observational Studies: Fact or Artifact? , 2011, Circulation. Cardiovascular quality and outcomes.
[37] Christopher E. Buller,et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2008, Journal of the American College of Cardiology.
[38] Jeffrey L. Anderson,et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. , 2008, Journal of the American College of Cardiology.
[39] A. Bavry,et al. Efficacy and Safety of Unfractionated Heparin Plus Glycoprotein IIb/IIIa Inhibitors During Revascularization for an Acute Coronary Syndrome: A Meta‐Analysis of Randomized Trials Performed With Stents and Thienopyridines , 2012, Clinical cardiology.
[40] Mandeep Singh,et al. An updated bleeding model to predict the risk of post-procedure bleeding among patients undergoing percutaneous coronary intervention: a report using an expanded bleeding definition from the National Cardiovascular Data Registry CathPCI Registry. , 2013, JACC. Cardiovascular interventions.
[41] Elliott S Fisher,et al. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. , 2007, JAMA.
[42] Sunil V. Rao,et al. Bleeding in Patients Undergoing Percutaneous Coronary Intervention: The Development of a Clinical Risk Algorithm From the National Cardiovascular Data Registry , 2009, Circulation. Cardiovascular interventions.
[43] Elizabeth R DeLong,et al. Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry. , 2010, Journal of the American College of Cardiology.